Inpharmatica, Schering, Shimadzu,Eidogen-Sertanty, KAI, Genedata, Nonlinear, Ariadne, Infocom, NLM | GenomeWeb

Inpharmatica Licenses Biopendium and Chematica to Schering

As BioInform reported in September [BioInform 09-29-05], Inpharmatica said last week that it has licensed its Biopendium and Chamatica technologies to Schering as part of a druggability assessment collaboration.

Inpharmatica said that Schering intends to use the technologies to support its protein-prioritization efforts.

The financial terms of the agreement were not disclosed.

Shimadzu to Distribute Phenomenome Discoveries' Metabolomics Software

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.